Comparison of the Effects of Probiotics Kidilact and Yomogi on Clinical Outcomes of Viral Diarrhea in Children

Document Type : Original Article(s)

Authors

1 School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

2 Associate Professor of Nutritional Sciences, Child Growth and Development Research Center, Isfahan University of Medical Sciences, Isfahan, Iran

3 Professor, Department of Pediatrics, School of Medicine, Child Growth and Development Research Center, Isfahan University of Medical Sciences, Isfahan, Iran

4 Assistant Professor of Biostatistics, Child Growth and Development Research Center, Isfahan University of Medical Sciences, Isfahan, Iran

5 Assistant Professor, Department of Pediatrics, School of Medicine, Child Growth and Development Research Center, Isfahan University of Medical Sciences, Isfahan, Iran

10.48305/jims.v43.i837.1425

Abstract

Background: Gastroenteritis is an infection of the gastrointestinal tract, and the most common cause of acute diarrhea is viral infection, especially rotavirus. Diarrhea is one of the leading causes of mortality and disability in children worldwide. Probiotics, as a supportive care, are prescribed by specialists for children with acute diarrhea. In the present study, we compare the severity of symptoms and the duration of hospitalization of children with viral diarrhea between two types of probiotics.
Methods: This was a cross-sectional study. 132 children aged 6 months to 6 years with a diagnosis of acute viral gastroenteritis were selected and divided into three groups of 44 participants each. The groups were Kidilact powder, Yomogi capsules, and a control group. They were compared based on the duration of hospitalization, frequency of diarrhea, and intravenous fluid intake. Findings were analyzed using binomial logistic regression and ANCOVA.
Findings: There were no significant differences in the mean frequency of diarrhea, duration of hospitalization (P = 0.018), duration of diarrhea (P = 0.012), and amount of intravenous fluid (P = 0.039) among the three groups. Even though the children in the Kidilact group had a more acute situation on the first and second days compared with controls, by the fourth day, the number of diarrheal episodes decreased rapidly among them. Similarly, in the Yomogi group, the mean number of diarrheal episodes decreased sharply by the third day. On the fifth day and beyond, almost all children in both groups were free of diarrhea (95.5% vs. 97.7%).
Conclusion: This study indicates that the use of Kidilact powder or Yomogi capsules has additional benefits to standard supportive care, and there was no statistical difference between the Yomogi and Kidilact groups.

Highlights

Motahar Heidari Beni: Google Scholar 

Roya Kelishadi:  Google Scholar

Maryam Yazdi: Google Scholar

Mohammad Ali Pourmirzaiee: Google Scholar

Keywords

Main Subjects

References

  1. Kliegman RM, Behrman RE, Jenson HB, Stanton BM. Nelson textbook of pediatrics. Elsevier Health Sciences; 2007.
  2. Guarino A, Ashkenazi S, Gendrel D, Lo Vecchio A, Shamir R, Szajewska H. European Society for Pediatric Gastroenterology, Hepatology, and Nutrition/European Society for Pediatric Infectious Diseases evidence‐based guidelines for the management of acute gastroenteritis in children in Europe: update 2014. J Pediatr Gastroenterol Nutr 2014; 59(1): 132-52.
  3. Khanna R, Lakhanpaul M, Burman-Roy S, Murphy MS. Diarrhoea and vomiting caused by gastroenteritis in children under 5 years: summary of NICE guidance. BMJ 2009; 338:
  4. King CK, Glass R, Bresee JS, Duggan C, Centers for Disease Control and Prevention. Managing acute gastroenteritis among children. MMWR Recomm Rep 2003; 52(RR-16): 1-16.
  5. Bányai K, Estes MK, Martella V, Parashar UD. Viral gastroenteritis. Lancet 2018; 392(10142): 175-86.
  6. Lee DK, Park JE, Kim MJ, Seo JG, Lee JH, Ha NJ. Probiotic bacteria, B. longum and L. acidophilus inhibit infection by rotavirus in vitro and decrease the duration of diarrhea in pediatric patients. Clin Res Hepatol Gastroenterol 2015; 39(2): 237-44.
  7. Wilhelmi I, Roman E, Sanchez-Fauquier A. Viruses causing gastroenteritis. Clin Microbiol Infect 2003; 9(4): 247-62.
  8. García-Menor E, García-Marín F, Vecino-López R, Horcajo-Martínez G, de Ibarrondo Guerrica-Echevarría MJ, Gómez-González P, et al. A multicenter, prospective, randomized controlled trial to evaluate the additional benefit of a multistrain synbiotic (Prodefen®) in the clinical management of acute viral diarrhea in children. Glob Pediatr Health 2016; 3: 2333794X16679587.
  9. Chhabra P, Payne DC, Szilagyi PG, Edwards KM, Staat MA, Shirley SH, et al. Etiology of viral gastroenteritis in children< 5 years of age in the United States, 2008–2009. J Infect Dis 2013; 208(5): 790-800.
  10. Osborne CM, Montano AC, Robinson CC, Schultz‐Cherry S, Dominguez SR. Viral gastroenteritis in children in Colorado 2006–2009. J Med Virol 2015; 87(6): 931-9.
  11. Hall AJ, Rosenthal M, Gregoricus N, Greene SA, Ferguson J, Henao OL, et al. Incidence of acute gastroenteritis and role of norovirus, Georgia, USA, 2004–2005. Emerg Infect Dis 2011; 17(8): 1381-8.
  12. Zimmerman CM, Bresee JS, Parashar UD, Riggs TL, Holman RC, Glass RI. Cost of diarrhea-associated hospitalizations and outpatient visits in an insured population of young children in the United States. Pediatr Infect Dis J 2001; 20(1): 14-9.
  13. Bonifait L, Charlebois R, Vimont A, Turgeon N, Veillette M, Longtin Y, et al. Detection and quantification of airborne norovirus during outbreaks in healthcare facilities. Clin Infect Dis 2015; 61(3): 299-304.
  14. Ahmadipour S, Mohsenzadeh A, Alimadadi H, Salehnia M, Fallahi A. Treating viral diarrhea in children by probiotic and zinc supplements. Pediatr Gastroenterol Hepatol Nutr 2019; 22(2): 162-70.
  15. Elliott EJ. Acute gastroenteritis in children. BMJ 2007; 334(7583): 35-40.
  16. Sartor RB. Therapeutic manipulation of the enteric microflora in inflammatory bowel diseases: antibiotics, probiotics, and prebiotics. Gastroenterology 2004; 126(6): 1620-33.
  17. Farthing M, Salam MA, Lindberg G, Dite P, Khalif I, Salazar-Lindo E, et al. Acute diarrhea in adults and children: a global perspective. J Clin Gastroenterol 2013; 47(1): 12-20.
  18. Guarner F, Sanders ME, Szajewska H, Cohen H, Eliakim R, Herrera-deGuise C, et al. World gastroenterology organisation global guidelines: probiotics and prebiotics. J Clin Gastroenterol 2024; 58(6): 533-53.
  19. Florez ID, Veroniki AA, Al Khalifah R, Yepes-Nunez JJ, Sierra JM, Vernooij RW, et al. Comparative effectiveness and safety of interventions for acute diarrhea and gastroenteritis in children: a systematic review and network meta-analysis. PLoS One 2018; 13(12): e0207701.
  20. Szajewska H, Skorka A, Ruszczyński M, Gieruszczak‐Białek D. Meta‐analysis: L actobacillus GG for treating acute gastroenteritis in children–updated analysis of randomised controlled trials. Aliment Pharmacol Ther 2013; 38(5): 467-76.
  21. Freedman SB, Pasichnyk D, Black KJ, Fitzpatrick E, Gouin S, Milne A, et al. Gastroenteritis therapies in developed countries: systematic review and meta-analysis. PLoS One 2015; 10(6): e0128754.
  22. Thomas DW, Greer FRAmerican Academy of Pediatrics Committee on Nutrition; American Academy of Pediatrics Section on Gastroenterology, Hepatology, and Nutrition. Probiotics and prebiotics in pediatrics. Pediatrics 2010; 126(6): 1217-31.
  23. Sniffen JC, McFarland LV, Evans CT, Goldstein EJ. Choosing an appropriate probiotic product for your patient: an evidence-based practical guide. PLoS One 2018; 13(12): e0209205.
  24. Narayanappa D. Randomized double blinded controlled trial to evaluate the
  25. efficacy and safety of Bifilac in patients with acute viral diarrhea. Indian J Pediatr 2008; 75(7): 709-13.
  26. Liu F, Wen K, Li G, Yang X, Kocher J, Bui T, et al. Dual functions of Lactobacillus acidophilus NCFM as protection against rotavirus diarrhea. J Pediatr Gastroenterol Nutr 2014; 58(2): 169-76.
  27. Chow SC, Shao J, Wang H, Lokhnygina Y. Sample size calculations in clinical research. New York: Chapman and Hall/CRC; 2017.
  28. Salari P, Nikfar S, Abdollahi M. A meta-analysis and systematic review on the effect of probiotics in acute diarrhea. Inflamm Allergy Drug Targets 2012; 11(1): 3-14.
  29. Dinleyici EC, Eren M, Ozen M, Yargic ZA, Vandenplas Y. Effectiveness and safety of Saccharomyces boulardii for acute infectious diarrhea. Expert Opin Biol Ther 2012; 12(4): 395-410.
  30. Allahverdi B, Ghorbani Vaghi A, Foroughi S, Miri M, Delfan B, Mozafari Kermani R. A randomized clinical trial with probiotics in acute viral diarrhea in Iranian children. Proceedings of the 22nd International Congress of Pediatrics, Tehran, Iran; 2010.
  31. Svensson L, Desselberger U, Estes MK, Greenberg HB. Viral gastroenteritis: molecular epidemiology and pathogenesis. New York: Academic Press; 2016.
  32. Freedman SB, Williamson-Urquhart S, Farion KJ, Gouin S, Willan AR, Poonai N, et al. Multicenter trial of a combination probiotic for children with gastroenteritis. N Engl J Med 2018; 379(21): 2015-26.
  33. Schnadower D, Tarr PI, Casper TC, Gorelick MH, Dean JM, O’Connell KJ, et al. Lactobacillus rhamnosus GG versus placebo for acute gastroenteritis in children. N Engl J Med 2018; 379(21): 2002-14.
  34. Nixon AF, Cunningham SJ, Cohen HW, Crain EF. The effect of Lactobacillus GG on acute diarrheal illness in the pediatric emergency department. Pediatr Emerg Care 2012; 28(10): 1048-51.
Journal of Isfahan Medical School
Volume 43, Issue 837
1st Week, January
January and February 2026
Pages 1425-1432

Files

History

  • Receive Date: 05 December 2025
  • Accept Date: 13 December 2025

Share

How to cite

Statistics